NCT05375084 - SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

April 12, 2024

Study Completion Date

July 15, 2024

Conditions

Non Small Cell Lung CancerSolid Tumor

Interventions

DRUG

BBP-398 with nivolumab

BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)

Trial Locations (15)

Roswell Park Cancer Institute, Buffalo

University of Pennsylvania (Abramson Cancer Center), Philadelphia

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

NEXT Oncology, Fairfax

Medical University of South Carolina (MUSC) - Hollings Cancer Center, Charleston

Memorial Regional Hospital (Memorial Cancer Institute), Hollywood

Moffitt Cancer Center, Tampa

Cleveland Clinic, Cleveland

Henry Ford Hospital, Detroit

Highlands Oncology, Springdale

MD Anderson Cancer Center, Houston

Millennium Research and Clinical Development, Houston

Scripps Clinic Torrey Pines, La Jolla

Providence Medical Foundation, Santa Rosa

Providence Portland Medical Center, Portland